



## Cardiac Devices: What Does the Future Hold for ACHD Patients?

Wednesday, October 27, 2021

7 p.m. – 8 p.m. EDT

Presenters: Dan Halpern, MD, and Adam Small, MD

### About the Webinar

Delivering the best care to adults with congenital heart disease (CHD) means using the best technology. Want to learn how this is done? If you answered yes, you will want to sign up for this ACHA webinar. We will discuss the medical devices that support, correct, and palliate CHD. From electrical monitoring devices... to valves implanted through veins... to surgical pumps – we will journey into the high-tech world and introduce you to the latest developments in ACHD care.

**REGISTER NOW:** <https://bit.ly/3gAzs6E>

### About the Presenters

Dan Halpern, MD, has been the medical director of the NYU ACHD program since 2015. He led the program for the first ACHA accreditation in New York state and its exponential growth. He has been an avid supporter for ACHD patients for the past decade and has specific interest in imaging in ACHD and care of pregnant women with CHD. Dr. Halpern graduated from the Israeli Technion Medical School and performed his ACHD fellowship at Boston Children's Hospital/Brigham and Women's Hospital. Dr. Halpern and the NYU team collaborates in multi-center trials and frequently host educational and support evenings for patients and their families.

Adam Small, MD, joined the NYU ACHD program in 2020. He has enjoyed ACHA's Walk for 1 in 100 and educational conferences—and looks forward to another chance to connect with ACHD community. He graduated from the University of Pennsylvania School of Medicine and stayed there to complete a dual residency in Internal Medicine and Pediatrics. He then completed cardiology and ACHD training at the University of California, Los Angeles. With Dr. Halpern and the NYU team, Dr. Small is actively involved in research endeavors, education, and support groups for adults with CHD in New York.

### About the Adult Congenital Heart Association

The Adult Congenital Heart Association (ACHA) is a national not-for-profit organization dedicated to **supporting individuals and families living with congenital heart disease and advancing the care and treatment available to our community.** ACHA empowers the more than nearly 2 million adults with CHD, their families, and the medical community by advancing access to resources and specialized care that improve patient-centered outcomes. For more information about ACHA, contact (888) 921-ACHA or visit [www.achaheart.org](http://www.achaheart.org).

This webinar was made possible in part by an unrestricted educational grant from Janssen, Inc. Pharmaceutical Companies of Johnson & Johnson.